Welcome to our dedicated page for Supernus Pharma news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharma stock.
Supernus Pharmaceuticals, Inc. (SUPN) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The company’s news flow reflects its role in neurology and psychiatry, with updates on commercial performance, pipeline progress, and strategic transactions.
Recent press releases highlight quarterly financial results, where Supernus reports net product sales for CNS therapies such as Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ONAPGO, and other products including MYOBLOC, XADAGO, and Osmolex ER. The company also reports collaboration revenue from ZURZUVAE, an oral treatment for postpartum depression, reflecting its collaboration with Biogen Inc. in the U.S. following Supernus’s acquisition of Sage Therapeutics, Inc.
Investors following SUPN news can expect coverage of product launches and commercialization updates, such as the U.S. launch and demand trends for ONAPGO, described as a subcutaneous apomorphine infusion device for motor fluctuations in adults with advanced Parkinson’s disease. Company announcements also discuss supply constraints and prioritization of existing patients when demand exceeds available inventory.
Supernus regularly issues news about its R&D pipeline, including clinical progress for SPN-817 in epilepsy, SPN-820 in depression, and SPN-443 for ADHD/CNS. In addition, the company announces participation in healthcare and therapeutics conferences hosted by investment banks and other organizations, providing forums where management discusses its CNS portfolio, financial performance, and strategy.
This news page aggregates these disclosures so readers can track earnings releases, collaboration developments around ZURZUVAE, clinical trial updates, and investor conference appearances related to Supernus Pharmaceuticals, Inc. (SUPN).
Summary not available.
Supernus Pharmaceuticals (Nasdaq: SUPN) plans to announce its first-quarter 2023 financial results on May 9, 2023, after market close. President and CEO Jack Khattar along with CFO Tim Dec will host a conference call at 4:30 p.m. ET to discuss these results and answer questions. The call will also be available via live webcast on the Company’s Investor Relations website. Supernus focuses on developing treatments for central nervous system (CNS) diseases, including approved products for conditions like epilepsy and Parkinson’s disease. The company also has a pipeline of novel CNS candidates aimed at various disorders.
Supernus Pharmaceuticals (Nasdaq: SUPN) has fully repaid its 0.625% Convertible Senior Notes due 2023, amounting to $402.5 million, along with $1.3 million in interest. The repayment was financed mainly using available cash and partially through a borrowing under its credit line. With this repayment, the 2023 Notes are no longer outstanding. Supernus continues to focus on developing treatments for CNS diseases, including epilepsy and Parkinson's disease, with ongoing development of novel product candidates.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced participation in two investor conferences in March 2023. The first is the Barclays Global Healthcare Conference on March 15, 2023, at the Loews Miami Beach Hotel, Florida. The second is the Jefferies Biotech on the Bay Summit on March 16, 2023, at The 1 Hotel South Beach, Florida. These events will feature management discussions focused on the company's biopharmaceutical products for central nervous system (CNS) diseases, including treatments for epilepsy and Parkinson's disease. Investors can arrange meetings with management through conference coordinators.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that CEO Jack Khattar will participate in a fireside chat and investor meetings at the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 9:50 a.m. ET. The conference runs from March 6-8, 2023, at the Boston Marriott Copley Place. Interested investors can set up meetings through the Cowen conference coordinator. A live audio webcast of Khattar's presentation will be available on Supernus' Investor Relations website, with a replay accessible for 60 days post-conference. Supernus focuses on CNS disease treatments, including epilepsy and ADHD, with ongoing development of new therapies.
Supernus Pharmaceuticals reported 2022 total revenues of $667.2 million, a 15% increase from 2021. The fourth quarter saw Qelbree® net sales of $23.6 million, up 29% from Q3, while GOCOVRI® sales reached $29.2 million, a 13% increase year-over-year. Total net product sales for the full year were $649.4 million, a 14% increase. The company anticipates 30% growth in 2023 revenues, excluding Trokendi XR® sales which face generic competition. Net earnings for Q4 stood at $25.5 million, with an EPS of $0.43.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced a new credit line agreement with UBS Bank USA, granting access to an uncommitted demand secured line of credit up to $150 million. The credit line can be drawn at any time, allowing the company to enhance its financial flexibility. Borrowing rates are determined based on either a fixed or variable interest rate linked to UBS’s funding rates. CEO Jack Khattar expressed confidence in this move to strengthen the company's balance sheet.
Supernus Pharmaceuticals (Nasdaq: SUPN) will report its Q4 and full year 2022 financial results on February 28, 2023, after market close. The conference call with CEO Jack Khattar and CFO Tim Dec is scheduled for 4:30 p.m. ET on the same day, followed by a Q&A session. A live webcast will be available on the company’s Investor Relations website. Supernus focuses on developing treatments for central nervous system diseases and has a diverse portfolio that includes approved therapies for various conditions such as epilepsy and Parkinson's disease.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that its President and CEO, Jack Khattar, will participate in a fireside chat and host investor meetings at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 10:30 a.m. ET. The event will take place in New York City from November 29 to December 1, 2022. Investors can schedule meetings through the conference coordinator and access a live audio webcast on the company's website, with an archived version available for 60 days afterward.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that its CEO, Jack Khattar, will present a company overview and update at two upcoming November conferences. The Stifel 2022 Healthcare Conference is scheduled for November 15, 2022, at 8:00 a.m. ET in New York. The 13th Annual Jefferies London Healthcare Conference will take place on November 17, 2022, at 9:05 a.m. ET / 2:05 p.m. GMT in London. Interested investors can arrange meetings through conference coordinators and access live webcasts on the Company's website.